Pharma

Indian pharma may face muted US growth in FY27 on gRevlimid pressure

Ind-Ra says Indian drugmakers will still see 10% revenue growth in FY27 driven by domestic demand and CDMO traction, despite weaker US sales after Revlimid expiry

Chemists warn PM that fake AI prescriptions are enabling illegal drug sales

AIOCD has urged the Prime Minister to ban AI-generated prescriptions, alleging they are being misused by unregulated e-pharmacies to sell restricted medicines, posing a serious public health risk

Uttar Pradesh govt's pharma investment kitty hits ₹38,000 crore

India's pharma market is estimated to touch $120 billion by 2030 while Uttar Pradesh accounts for roughly 17 percent of domestic sales

USV to acquire 79% stake in Wellbeing Nutrition at ₹1,583 cr valuation

USV, a pharmaceutical and biotechnology company, will acquire a 79 per cent stake in Wellbeing Nutrition at a valuation of Rs 1,583 crore. USV has signed a definitive agreement to acquire a 79 per cent equity stake in Nutritionalab Pvt Ltd, which owns "Wellbeing Nutrition", according to a joint statement. This includes 35 per cent from the founder Avnish Chhabria and 44 per cent from existing shareholders. Its investors -- Early backers Fireside Ventures and Hindustan Unilever -- will divest their collective 40 per cent stake. This Rs 1,583 crores all-cash transaction represents the largest exit in India's health and wellness startup space to date, it added. This strategic expansion of USV, a leading player in diabetes and cardiac care, into consumer wellness is aligned with its expansion across the healthcare continuum. "The addition of Wellbeing Nutrition reinforces USV's evolution into a comprehensive healthcare powerhouse spanning both therapeutic excellence and consumer ...

Medtech manufacturing industry divided on policy for refurbished devices

Domestic device makers warn of safety and dumping risks, while MNC bodies back affordability benefits as the Centre reviews policy on refurbished high-end medical device imports

Zydus Lifesciences Q3 net profit rises 9% on strong US and India growth

Zydus Lifesciences posted higher Q3 profit and revenue, aided by strong growth in the US and India businesses, improved margins, and steady momentum in generics, specialty and chronic segments

Centre mandates drug cos to submit post-approval changes for new drugs

Draft amendment seeks mandatory reporting of manufacturing and quality changes to drug regulator

Health-tech startup Tata 1mg eyes 500 offline stores by year-end

The move signals a sharper push towards omnichannel growth amid continued regulatory uncertainty in e-pharmacy

Supriya Life Sciences bets on regulated markets with new facility

The Mumbai-based pharma company has commissioned a ₹165-crore formulations plant at Ambernath to support contract manufacturing and strengthen its presence in regulated global markets

India-New Zealand trade deal finalised: Which sectors are set to gain?

The deal includes sweeping tariff cuts, expanded services access, enhanced labour mobility and a long-term investment commitment

Biocon launches drugs for diabetes and obesity treatment in Netherlands

The Netherlands launch builds on Biocon's entry into the UK in February, where it received regulatory approval for liraglutide from the Medicines and Healthcare Products Regulatory Agency

300 products hold huge potential for Indian exporters in Russia: Official

As many as 300 products, including that of engineering goods, pharma, agri, and chemicals, hold huge potential for Indian exporters to push their shipments to Russia as the two countries target USD 100 billion trade by 2030, an official said. At present, India's exports of these goods to Russia stood at USD 1.7 billion, as against Russia's USD 37.4 billion in imports. "This stark disparity demonstrates the substantial complementary export space India can target," the official said, adding increasing exports will also help India bridge its trade deficit with Russia, which stood at USD 59 billion. These high-potential products have been selected by the commerce ministry by analysing complementary basket of products -- mapping India's supply visa-a-vis Russia's demand across key sectors, the official added. The most promising areas mirror India's rising global strengths are engineering goods, pharmaceuticals, chemicals and agriculture, all of which correspond to substantial unmet dema

Novo Nordisk moves HC to stop Sun Pharma's weight-loss drug launch

The dispute centres on Novo Nordisk's Indian patents for semaglutide, which it markets globally as Ozempic and Wegovy for Type 2 diabetes and weight management

Generic drugmakers to slash price plans as Novo cuts Wegovy rates

Novo Nordisk cut Wegovy prices by up to 37 per cent across different doses to compete with rival drug Mounjaro from Eli Lilly

Rupee's fall to boost IT & Pharma, but is it too soon to bet? Analysts weigh in

India’s rupee has fallen to a new low against the US dollar, raising concerns across markets. But analysts say not everyone loses.

Novo Nordisk cuts weight-loss drug Wegovy prices by up to 37% in India

Move comes in a bid to gain more space in India's anti-obesity market dominated by Mounjaro

Eli Lilly to buy gene therapy developer Adverum in about $262 mn deal

The deal will give Lilly access to Adverum's gene therapy candidate, Ixo-vec, and underscores the U.S. drugmaker's focus on such treatments

Govt to bring law for strict quality checks, monitoring of drugs, cosmetics

Amid growing demand for stricter compliance with safety and quality control norms for medical products, the Centre is framing a law to strengthen the legal framework for drug quality testing and market surveillance, along with regulation of medical devices and cosmetics. One of the major reasons behind the drafting of the law is the repeated complaints and concerns flagged by health regulators across the globe, including the WHO, over serious quality lapses by Indian drug manufacturers. The draft of the 'Drugs, Medical Devices and Cosmetics Act 2025', which the government aims to introduce in the upcoming Winter session of Parliament, was presented by Drugs Controller General of India (DCGI) Dr Rajeev Raghuvanshi at a high-level meeting of the Union health ministry held on Tuesday, the sources said. The meeting was chaired by Union Health Minister J P Nadda. During the meeting, senior officials from the Drugs Controller General of India (DCGI) and the Central Drugs Standard Control

Tamil Nadu cancels licence of cough syrup maker linked to child deaths

"The manufacturing licenses of Sresan Pharmaceuticals have been completely cancelled, and the company has been shut down," the state government said in a statement

Mohan Yadav blames Tamil Nadu for poor cooperation in cough syrup case

After 24 child deaths linked to toxic cough syrup, Madhya Pradesh CM Mohan Yadav accuses Tamil Nadu of not cooperating in the investigation into drug safety lapses